Authors' objectives: The National Screening Advisory Committee (NSAC) was established in 2019 by the Minister for Health as an independent advisory committee to play a significant strategic role in the development and consideration of population-based screening programmes in Ireland. At the request of the Department of Health, the Health Technology Assessment (HTA) directorate within the Health Information and Quality Authority (HIQA) undertakes evidence synthesis and provides evidence-based advice to NSAC on behalf of the Minister for Health. In September 2021, NSAC requested that HIQA undertake a health technology assessment of the potential addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme (NNBSP) in Ireland. The protocol document outlines the evidence synthesis approach that HIQA’s evaluation team will use to complete this piece of work.

Project Status: Completed

URL for project: https://www.hiqa.ie/reports-and-publications/health-technology-assessment/hta-addition-severe-combined-immunodeficiency

URL for protocol: https://www.hiqa.ie/sites/default/files/2022-03/SCID_protocol.pdf

Year Published: 2023

URL for published report: https://www.hiqa.ie/reports-and-publications/health-technology-assessment/hta-addition-severe-combined-immunodeficiency

Requestor: National Screening Advisory Committee (NSAC)

English language abstract: An English language summary is available

Publication Type: Full HTA

Country: Ireland

Organisation Name: Health Information and Quality Authority (HIQA)

Contact Address: Health Information and Quality Authority, George's Court, George's Lane,Smithfield, Dublin 7. PH : + 353 (01) 814 7464

Contact Name: info@hiqa.ie

Contact Email: info@hiqa.ie